ArticleInvestigative ophthalmology & visual science2026
Novel Role of AcylCoA: Cholesterol Acyltransferase 1/Sterol O-Acyltransferase 1 (ACAT1/SOAT1) in Diabetic Retinopathy.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
Purpose: Hypercholesterolemia has been linked to inflammation and vascular dysfunction in diabetic retinopathy (DR). Excessive cholesterol ester (CE) production in macrophages can induce increases in inflammatory and angiogenic cytokines. AcylCoA:cholesterol acyltransferase 1/Sterol O-acyltransferase 1 (ACAT1/SOAT1) is responsible for cholesterol esterification. Here we determine its role in diabetic retinopathy (DR). We hypothesized that DR-induced increases in ACAT1/SOAT1-mediated CE formation triggers retinal inflammation and injury. Methods: Ins2Akita mice were treated with the ACAT1/SOAT1 inhibitor K604 (10 mg/kg, intraperitoneally) from 10 to 12 weeks or eight to 10 months. Plasma and retinal CE, oxidative stress, inflammation, vascular pathology, and retinal function were assessed by ELISA, qPCR, Western blot, leukostasis and permeability assays, electroretinography (ERG), and OptoMotry. ACAT1/SOAT1 expression and CE levels were assayed in retinal sections and vitreous samples from DR donors. Results: Retinas from 12-week-old Ins2Akita mice exhibited increases in CE and superoxide, and expression of ACAT1/SOAT1, LDLR, TREM1, MCSF, and VEGF along with leukostasis, hyperpermeability, acellular capillaries, retinal ganglion cell loss, and impaired ERG and visual acuity function. K604 treatment inhibited these changes. Retinas from 10-month-old Ins2Akita mice also showed increased ACAT1/SOAT1, LDLR, TREM1, MCSF, CE, superoxide, hyperpermeability, and impaired ERG and acuity responses that were inhibited by K604. These protective effects were independent of changes in systemic glucose or body weight. Conclusions: ACAT1/SOAT1 inhibition normalizes ACAT1/SOAT1 expression and CE formation, prevents oxidative stress and inflammation, and limits vascular and retinal dysfunction in both early- and late-stage DR. These findings identify ACAT1/SOAT1 as a promising target for treatment of DR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.